We integrated immunohistochemistry (IHC) and data mining analyses to determine LIMCH1 expression in tumor specimens; the chi-square test was used to explore the correlation between clinicopathologic factors and LIMCH1 expression in LUAD; Kaplan-Meier curves and the Cox proportional hazards model were used to investigate the clinical prognostic role of LIMCH1 expression in patients with LUAD; and DAVID enrichment and gene set enrichment analysis (GSEA) were used to determine the underlying molecular mechanism. The gene discussed is LIMCH1; the disease is neoplasm.